SINGAPORE, October 27, 2025 /PRNewswire/ — Raffles Medical Group (the Group) and Genetic solutions signed a memorandum of understanding on October 22, 2025 to streamline patient recruitment for oncology clinical trials, marking an important milestone in the advancement of precision medicine in Southeast Asia.
As part of this partnership, the Group and Gene Solutions will collaborate to identify patients eligible for clinical trials sponsored by the pharmaceutical industry. Patients undergoing Comprehensive Genomic Profiling (CGP) through Gene Solutions will be automatically screened for eligibility. The Group’s clinical trials unit will work closely with local oncologists to facilitate patient recruitment. This initiative aims to make cutting-edge cancer treatments more accessible and support more equitable access to clinical trials in the region.
![[From left to right] Mr. Wilson Lai, Managing Director of Raffles Medical Indochina and Dr. Nguyen Huu Nguyen, Co-Founder and Deputy CEO of Gene Solutions.](https://www.times24h.com/wp-content/uploads/2025/10/Raffles-Medical-Group-partners-with-Gene-Solutions-to-expand-access.jpg "[From left to right] Mr. Wilson Lai, Managing Director of Raffles Medical Indochina and Dr. Nguyen Huu Nguyen, Co-Founder and Deputy CEO of Gene Solutions.")
Offering patients new opportunities
Through this collaboration, patients in Vietnam and Southeast Asia will have better opportunities to participate in innovative cancer studies without traditional barriers. From initial genetic testing and eligibility screening to ongoing clinical care and support, patients and their families will receive guidance to navigate complex treatment journeys with confidence and clarity.
Understanding precision medicine
Modern cancer treatments go beyond “one-size-fits-all” approaches. Precision therapies, such as targeted drugs and immunotherapies, work by focusing on specific genetic changes or immune pathways that promote cancer growth. Although many targeted therapies are already approved, there are still many genes and mutations without effective drugs. This is why more clinical trials are essential to evaluate new treatments and bring more hope to patients.
As Gene Solutions’ signature oncology test, K-4CARE, states in its tagline: “Revealing the Details, Unleashing Hope”“The more we understand the DNA and RNA profile of a tumor, the more likely patients are to access approved drugs or participate in global clinical trials. To identify these opportunities, doctors must look in depth at the tumor’s genetic code. This is where next generation sequencing (NGS) comes in. Gene Solutions uses NGS to decode the genetic profile of cancer and identify patients who may respond to advanced treatments. Without these tests, many patients would never know they are eligible for life-changing clinical trials.
An expert’s perspective
Professor Yasuo Saijo, Medical Oncologist at Raffles Medical Indochina, shared: “For oncologists, genomic insights are transforming the way we approach cancer care. By understanding the genetic and transcriptomic profile of the tumor, we can make more informed decisions, such as selecting the right treatment at the right time, tailoring treatment to each patient’s unique biology, and improving outcomes and quality of life.
Raffles Dedicated Clinical Trials Unit
Raffles Medical Group brings decades of experience in providing high-quality cancer care and conducting clinical trials. Through its Raffles Cancer Center and its dedicated clinical trials unit, the Group has participated in more than 50 international studies, guaranteeing patients access to promising therapies while respecting the highest safety and ethical standards. Its multidisciplinary approach and advanced facilities in Singapore make it a trusted destination for complex cancer care and innovative treatments across Southeast Asia.
First step: KRYSTAL-7
The collaboration will begin with KRYSTAL-7, a global study enrolling participants diagnosed with KRAS G12C mutated non-small cell lung cancer (NSCLC) who have not received any prior treatment. This is the first of many clinical trials planned under the partnership, reflecting a shared commitment to improving patient outcomes through innovation and international cooperation.
“Raffles Medical Group is excited to partner with Gene Solutions to bring cutting-edge clinical trials to patients in Vietnam and across Southeast Asia. This collaboration reflects our commitment to advancing precision medicine and improving patient outcomes,” said Mr. Wilson Lai, Managing Director of Raffles Medical Indochina.
“With one of the largest market shares for comprehensive genomic profiling in Southeast Asia, Gene Solutions can pre-screen a large patient pool and identify those who could benefit from clinical trials. By combining this capability with Raffles’ clinical excellence, we can accelerate access to promising new therapies for patients across the region,” says Dr. Nguyen Huu Nguyen, co-founder and deputy CEO of Gene. Solutions.
About Genetic Solutions
Gene Solutions is a multinational biotechnology company at the forefront of genetic testing and research innovation in the Asia-Pacific region. Leveraging next-generation sequencing (NGS) and artificial intelligence, the company offers a comprehensive portfolio of advanced solutions, including:
- Next-generation non-invasive prenatal testing (NIPT), which covers both fetal abnormalities and maternal health indicators.
- Clinically validated multi-cancer screening using multi-omic circulating tumor DNA (ctDNA) technology for early detection and localization of tumor origin.
- Comprehensive genomic and transcriptomic profiling combined with clinically validated cDNA-based molecular residual disease (MRD) monitoring to guide precision treatment and track disease progression.
With more than two million genetic tests completed since 2017, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and contributions to the advancement of precision medicine through clinical studies, technology development, and regional collaborations. For more information, please visit genesolutions.com.
About Raffles Medical Group
Founded in 1976, Raffles Medical Group is one of the region’s leading integrated private healthcare providers, offering a continuum of services from primary and tertiary care to health insurance to populations across Asia. A proudly Singaporean brand, RMG is listed on the Singapore Stock Exchange (SGX: BSL) and operates in 14 cities across five countries in Asia. This network includes four hospitals and more than 100 multidisciplinary clinics, offering services such as medical screening, specialty care, diagnostic radiology, dentistry and traditional Chinese medicine. With approximately 2,900 employees, RMG brings more than 48 years of expertise and trusted healthcare to more than 2.8 million patients across our network as a trusted healthcare partner. For more information, please visit rafflesmedicalgroup.com.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/raffles-medical-group-partners-gene-solutions-to-expand-access-to-global-cancer-clinical-trials-302595012.html
SOURCE Gene Solutions Genomics Pte Ltd
